rs3754551
Variant names:
Your query was ambiguous. Multiple possible variants found:
Variant summary
Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_014171.6(CRIPT):c.16+220C>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0434 in 152,214 control chromosomes in the GnomAD database, including 245 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.043 ( 245 hom., cov: 31)
Consequence
CRIPT
NM_014171.6 intron
NM_014171.6 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: -1.85
Publications
2 publications found
Genes affected
CRIPT (HGNC:14312): (CXXC repeat containing interactor of PDZ3 domain) This gene encodes a protein that binds to the PDZ3 peptide recognition domain. The encoded protein may modulates protein interactions with the cytoskeleton. A mutation in this gene resulted in short stature with microcephaly and distinctive facies. [provided by RefSeq, Jun 2014]
CRIPT Gene-Disease associations (from GenCC):
- Rothmund-Thomson syndrome, type 3Inheritance: AR Classification: STRONG, MODERATE, LIMITED Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.83).
BP6
Variant 2-46617518-C-G is Benign according to our data. Variant chr2-46617518-C-G is described in ClinVar as [Benign]. Clinvar id is 1226796.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.177 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0435 AC: 6617AN: 152096Hom.: 246 Cov.: 31 show subpopulations
GnomAD3 genomes
AF:
AC:
6617
AN:
152096
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.0434 AC: 6611AN: 152214Hom.: 245 Cov.: 31 AF XY: 0.0472 AC XY: 3512AN XY: 74418 show subpopulations
GnomAD4 genome
AF:
AC:
6611
AN:
152214
Hom.:
Cov.:
31
AF XY:
AC XY:
3512
AN XY:
74418
show subpopulations
African (AFR)
AF:
AC:
375
AN:
41550
American (AMR)
AF:
AC:
512
AN:
15286
Ashkenazi Jewish (ASJ)
AF:
AC:
221
AN:
3470
East Asian (EAS)
AF:
AC:
964
AN:
5158
South Asian (SAS)
AF:
AC:
319
AN:
4810
European-Finnish (FIN)
AF:
AC:
986
AN:
10602
Middle Eastern (MID)
AF:
AC:
21
AN:
294
European-Non Finnish (NFE)
AF:
AC:
3061
AN:
68020
Other (OTH)
AF:
AC:
89
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.499
Heterozygous variant carriers
0
309
617
926
1234
1543
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
299
AN:
3478
ClinVar
Significance: Benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
Jun 18, 2021
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.